Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Word is Getting Out!

<< Previous

Bullboard Posts

Next >>

Post by Azzak34on May 14, 2024 5:45am

209 Views

Post# 36038109

Word is Getting Out!

https://news.sky.com/story/doctor-still-cancer-free-almost-a-year-after-incurable-brain-tumour-diagnosis-thanks-to-his-own-pioneering-treatment-13135621

Prof Long added: "We've shown that... you can activate the immune system and do it very well and this is now a foundational first step to change the field and the way drugs are explored in brain cancer."

<< Previous

Bullboard Posts

Next >>

Here are three global stocks you should watch